135 related articles for article (PubMed ID: 25852062)
1. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract][Full Text] [Related]
2. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
Dunn GP; Cheung HW; Agarwalla PK; Thomas S; Zektser Y; Karst AM; Boehm JS; Weir BA; Berlin AM; Zou L; Getz G; Liu JF; Hirsch M; Vazquez F; Root DE; Beroukhim R; Drapkin R; Hahn WC
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1102-7. PubMed ID: 24385586
[TBL] [Abstract][Full Text] [Related]
3. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
4. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
5. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
[TBL] [Abstract][Full Text] [Related]
6. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
Sung CO; Song IH; Sohn I
Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
[TBL] [Abstract][Full Text] [Related]
9. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
10. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
Cuello MA; Kato S; Liberona F
J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
[TBL] [Abstract][Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
12. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
14. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
[TBL] [Abstract][Full Text] [Related]
15. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
17. Amplification of 11q13 in ovarian carcinoma.
Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
[TBL] [Abstract][Full Text] [Related]
18. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
